S

Sanofi

Global pharma company; vaccines and R&D

Regulatory Site Officer

Full-TimeUpdated on 10/15/2026Deadline 11/15/26
No salary listed
Mid, Senior
Bachelor's, Master's
Beijing, China
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A degree in Science, Pharmacy, or equivalent is required.
  • An MSc-level qualification in Science is ideally preferred.
  • Three to five years of industry experience, preferably in biopharma or a related regulated industry with a focus on Regulatory Affairs.
  • In-depth knowledge of the BLA process, Annex 1 requirements, CTD format, and associated regulatory requirements in the United States, Europe, and China.
  • Strong technical regulatory writing skills and experience with health authority interactions.
  • Knowledge of GMP and quality systems.
  • Knowledge and experience in regulatory affairs for biologics, including regulatory strategy and regulatory intelligence.
  • Experience with NMPA regulatory requirements.
  • Knowledge of Commissioning & Qualification, Process Validation Lifecycle, and Quality by Design principles.
  • Scientific writing skills.
  • Fluent English and Chinese.
  • Familiarity with strategic planning, balanced judgment, and risk analysis.
  • Skills in decision-making, people development, negotiation, influencing, business partnering, communication, leadership, and assertiveness.
  • Knowledge of regulatory intelligence and compliance systems, regulatory submissions management, CTD writing, quality systems, Quality Risk Management, GxP and health-regulated regulations, and international and FDA exposure.
Responsibilities
  • Ensure compliance of IFB insulin API products with relevant product registrations, laws, regulations, standards, and guidelines for assigned markets.
  • Author and support creation of dossiers, variations, CTD sections impacted by changes, and renewals of IFB product registrations, with a focus on local-language regulatory documentation following NMPA guidelines.
  • Support regulatory impact assessments of changes to IFB products and services, particularly China regulations and dossier impact.
  • Assist in executing the regulatory compliance maintenance program for site products.
  • Monitor regulatory environment changes and support impact analysis for IFB.
  • Support regulatory aspects of product lifecycle management for IFB products.
  • Contribute to site master file writing and maintenance.
  • Support health authority interactions and responses to queries, and contribute to health authority reporting when applicable.
  • Participate in project work stream meetings and planning sessions, and coordinate regulatory deliverables.
  • Support maintenance and reporting of regulatory performance metrics.
  • Provide regulatory support and documentation during site inspections.
  • Support quality systems implementation and GMP compliance.
  • Collaborate with quality teams to ensure regulatory-quality alignment.
  • Coordinate with Quality Regulatory InsuLINK to align regulatory strategy implementation across the InsuLINK program.
  • Contribute to the C&Q&V strategy from a regulatory and dossier impact assessment perspective.
  • Support quality culture and GMP compliance performance.
  • Provide regular reporting to the IFB Quality Lead and dotted-line reporting to the Lead RSO InsuLINK.
Desired Qualifications
  • Three to five years of industry experience, preferably in biopharma or a related regulated industry with a focus on Regulatory Affairs.
  • An MSc-level qualification in Science.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)